|Bid||45.75 x 800|
|Ask||45.83 x 900|
|Day's Range||45.71 - 46.57|
|52 Week Range||37.01 - 59.59|
|Beta (3Y Monthly)||0.85|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In 2016 Habib Dable was appointed CEO of Acceleron Pharma Inc. (NASDAQ:XLRN). This report will, first, examine the CEO...
Acceleron (XLRN) delivered earnings and revenue surprises of -41.67% and 1.95%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Celgene (CELG) beats on earnings and sales in second-quarter 2019. The company raises full-year revenue guidance on solid Pomalyst and Abraxane performances.
Shares of biotech company Celgene rose Tuesday after the FDA accepted its application for an Acceleron Pharma-partnered anemia treatment in beta thalassemia and some blood cancers.
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
Acceleron (XLRN) delivered earnings and revenue surprises of -10.45% and -24.76%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 74 cents. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...
Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.
Within the Life Sciences segment, high investment in several geographies along with product launches and new technologies is resulting in a strong upside for Bio-Rad (BIO).
For the fiscal third quarter, Telenav (TNAV) expects total revenues between $49 million and $53 million, while net loss is anticipated to be $7 million-$9 million.
The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or less stagnant Europe, weighed heavily on the minds of investors. Both the S&P 500 and Russell 2000 sank as a result, with the Russell 2000, […]